Company Overview

Company name: Artelo Biosciences (NAS: ARTL)
Description: Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is focused on discovering, licensing, developing and commercializing treatments that control the endocannabinoid system. The company seeks to pursue technologies and programs that offer proprietary approaches to cannabinoid-based therapies, including those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds that promote the effectiveness of the endocannabinoid system. The firm’s flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.
Year founded: 2011
Parent company:
Industry: Healthcare | Group: | Code:
Website: www.artelobio.com
Employees: 1
City: La Jolla
State: California
Country: United States
Region:

Financial Highlights

Start up capital raised (USD Million):
Business status: Generating Revenue/Not Profitable
Ownership: Publicly Held
Exchange: NAS
Ticker: ARTL
Revenue (USD Million): 0.00
Gross profit (USD Million):
Net income (USD Million) -4.47
Enterprise value: 2.40
Earnings before interest, tax, depreciation and amortization (EBITDA): -4.47
Fiscal period: TTM 3Q2020
Financing Status:
Number of active investors:
Profile last updated: 13-Oct-2020
Last known valuation:
Last known valuation date: